drugset / Trial / NCT00003761

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

NCT00003761

NaSingle-groupOpen-labelTreatment

Summary

This protocol is designed to evaluate the side effects of rV-DF3/MUC1 and to determine the safest dose which should be used in the treatment of breast cancer.

Timeline

Start
1999-03-03
Primary completion
2001-04-20
Completion
2001-10-19

Drugs

EvaluationDrugModalityDoseRoute
Subject MUC1 Vaccine 4.76e+06 unknown Other
Subject MUC1 Vaccine 4.76e+07 unknown Other
Subject MUC1 Vaccine 4.76e+08 unknown Other

Indications